HDAC6 is a well-known target. We’ve got a breakthrough approach.
Histone DeACetylase 6 (HDAC6) is not like other HDACs. Its effects are not mediated through the nucleus nor does it directly affect epigenetic pathways. It’s a cytoplasmic regulator implicated in everything from microtubule transport to autophagy.
Microtubule Transport
Chaperone
Response
Autophagy &
Lipophagy
Aggresome Formation & Protein Clearance
Oxidative
Stress
Neurite Outgrowth & Regeneration
Innate Immunity & Inflammation
Decades of research and numerous animal studies have validated its therapeutic potential, but to date extensive industry efforts to drug it with hydroxamic acid and oxadiazole-based inhibitors have been suboptimal — not because the target was wrong, but because the molecules were not suitable.
At Augustine Therapeutics, we’ve solved these challenges with a novel non-hydroxamate, non-hydrazide producing chemotype: selective, safe, and built for chronic disease.
A single target with broad opportunities across neurologic and cardio-metabolic diseases
Our lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth Disease (CMT), but our pipeline doesn’t stop there. We’re advancing a portfolio designed to maximize the therapeutic potential of HDAC6, targeting neuromuscular, neurodegenerative and cardio-metabolic diseases.
“Our mapping of the HDACi landscape has made us confident that Augustine’s innovative and rigorous approach to medicinal chemistry has yielded molecules with potential to be best-in-class. HDAC6 inhibition shows great promise in many indications, and we are enthused to start our collaboration with Augustine’s top-tier management team”
Decades of experience, one bold mission
Our leadership combines deep scientific expertise with proven drug development success. With experience across pharma, biotech, and academia, we are pioneering a new generation of HDAC6 inhibitors that are selective, safe, and effective.
.png)
